HIGHLIGHTS
- who: Cheng Liu from the Columbia University Irving Medical Center, United States have published the research: Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F] fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer, in the Journal: (JOURNAL)
- what: The enrolled patients had performed 18F-FES scans for one of the following purposes: 1) predicting response to fulvestrant, a phase II study (NCT03507088, n=23) or 2) identifying the ER status of metastatic lesions for clinical practice (n=12). The authors report that patients with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.